Identification

Name
Resveratrol
Accession Number
DB02709  (EXPT02968)
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two structural isomers: cis-(Z) and trans-(E), with the trans-isomer shown in the top image. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.

Structure
Thumb
Synonyms
  • (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
  • (E)-resveratrol
  • 3,4',5-trihydroxy-trans-stilbene
  • 3,4',5-trihydroxystilbene
  • 3,5,4'-trihydroxystilbene
  • 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
  • trans-resveratrol
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Co-VeratrolResveratrol (400 mg/mg) + Folic Acid (.8 mg/mg) + Methylcobalamin (5 mg/mg) + Ubiquinol (200 mg/mg)CapsuleOralHome Aide Diganostics, Inc.2015-08-01Not applicableUs
DyzbacResveratrol (50 mg/1) + Ascorbic acid (125 mg/1) + Cholecalciferol (500 [iU]/1) + Leucovorin (1 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal Phosphate (12.5 mg/1) + Ubidecarenone (25 mg/1)TabletOralBasiem2015-11-052016-01-09Us
MebolexResveratrol (50 mg/1) + Ascorbic acid (125 mg/1) + Cholecalciferol (.0125 mg/1) + Leucovorin (1 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal Phosphate (12.5 mg/1) + Ubidecarenone (25 mg/1)TabletOralSolubiomix2015-10-282016-01-09Us
Medi-10Resveratrol (83 mg/1) + Acetylcysteine (200 mg/1) + Cholecalciferol (1000 [iU]/1) + Chromium picolinate (1 mg/1) + Levomefolate calcium (2.5 mg/1) + Lipoic Acid (200 mg/1) + Methylcobalamin (2.5 mg/1) + Nicotinamide (10 mg/1) + Pyridoxal Phosphate (20 mg/1) + Ubidecarenone (16 mg/1)CapsuleOralMedicap Laboratories Inc.2015-05-012016-01-15Us
Categories
UNII
Q369O8926L
CAS number
501-36-0
Weight
Average: 228.2433
Monoisotopic: 228.07864425
Chemical Formula
C14H12O3
InChI Key
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChI
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
IUPAC Name
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
SMILES
OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1

Pharmacology

Indication

Being investigated for the treatment of Herpes labialis infections (cold sores).

Pharmacodynamics

Resveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties.

Mechanism of action

Resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914].

TargetActionsOrganism
URibosyldihydronicotinamide dehydrogenase [quinone]Not AvailableHuman
UCasein kinase II subunit alphaNot AvailableHuman
UProstaglandin G/H synthase 1
inhibitor
Human
UProstaglandin G/H synthase 2
inhibitor
Human
UArachidonate 15-lipoxygenaseNot AvailableHuman
UArachidonate 5-lipoxygenaseNot AvailableHuman
UAryl hydrocarbon receptorNot AvailableHuman
UPhosphatidylinositol 4-kinase type 2-betaNot AvailableHuman
UIntegrin alpha-5Not AvailableHuman
UIntegrin beta-3Not AvailableHuman
UAmyloid beta A4 proteinNot AvailableHuman
UAlpha-synucleinNot AvailableHuman
UEstrogen receptor alphaNot AvailableHuman
UMelatonin receptor type 1ANot AvailableHuman
UMelatonin receptor type 1BNot AvailableHuman
UC-type lectin domain family 14 member ANot AvailableHuman
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
UNuclear receptor subfamily 1 group I member 3Not AvailableHuman
USolute carrier family 2, facilitated glucose transporter member 1Not AvailableHuman
UCarbonyl reductase [NADPH] 1
inhibitor
Human
UPeroxisome proliferator-activated receptor alphaNot AvailableHuman
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
URAC-alpha serine/threonine-protein kinase
inhibitor
Human
UFar upstream element-binding protein 2Not AvailableHuman
UTyrosine--tRNA ligase, cytoplasmic
inhibitor
Human
Absorption

High absorption but very low bioavailability.

Volume of distribution
Not Available
Protein binding

Strong affinity towards protein binding.

Metabolism

Hepatic. Rapidly metabolized and excreted.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Resveratrol.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 5-androstenedione.Experimental, Illicit
AbciximabResveratrol may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Resveratrol can be increased when it is combined with Abiraterone.Approved
AcebutololResveratrol may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolResveratrol may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Resveratrol.Experimental
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Resveratrol.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Resveratrol.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.Approved
AliskirenResveratrol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Resveratrol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aloxiprin.Experimental
AlprenololResveratrol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Resveratrol.Approved, Investigational
AlteplaseResveratrol may increase the anticoagulant activities of Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide.Approved
AmilorideResveratrol may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid.Approved
AnagrelideResveratrol may increase the anticoagulant activities of Anagrelide.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Resveratrol.Approved, Investigational, Withdrawn
AncrodResveratrol may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Resveratrol.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Resveratrol is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Resveratrol.Investigational
AnistreplaseResveratrol may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.Approved, Investigational
Antithrombin III humanResveratrol may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Antrafenine.Approved
ApixabanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Resveratrol.Investigational
ApramycinResveratrol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Resveratrol.Approved, Investigational
ArbekacinResveratrol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinResveratrol may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanResveratrol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololResveratrol may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineResveratrol may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinResveratrol may increase the anticoagulant activities of Astaxanthin.Investigational
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Resveratrol.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Atamestane.Investigational
AtenololResveratrol may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Resveratrol.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.Approved, Investigational
AzithromycinThe metabolism of Resveratrol can be decreased when combined with Azithromycin.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Resveratrol.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Resveratrol.Approved, Investigational
BatroxobinResveratrol may increase the anticoagulant activities of Batroxobin.Experimental
BazedoxifeneResveratrol may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminResveratrol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololResveratrol may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinResveratrol may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinResveratrol may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Resveratrol.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Resveratrol.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Resveratrol.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Resveratrol.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Resveratrol.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone.Approved, Vet Approved
BetaxololResveratrol may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Resveratrol.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
BevantololResveratrol may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Resveratrol.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol.Approved, Investigational
BisoprololResveratrol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinResveratrol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololResveratrol may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Resveratrol can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Resveratrol.Approved
BrinaseResveratrol may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Resveratrol.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Resveratrol.Investigational
BucindololResveratrol may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bufexamac.Approved, Experimental
BuflomedilResveratrol may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolResveratrol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Resveratrol.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Resveratrol.Approved
BupranololResveratrol may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideResveratrol may increase the antiplatelet activities of Butylphthalide.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Resveratrol.Approved
CaffeineThe metabolism of Resveratrol can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Resveratrol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Candoxatril.Experimental
CangrelorResveratrol may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabResveratrol may increase the anticoagulant activities of Caplacizumab.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Captopril.Approved
CarbamazepineThe metabolism of Resveratrol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Resveratrol.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.Approved, Vet Approved, Withdrawn
CarteololResveratrol may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Resveratrol.Approved, Investigational
CeliprololResveratrol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Resveratrol.Approved, Withdrawn
CertoparinResveratrol may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
ChlorotrianiseneResveratrol may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Resveratrol.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cilazapril.Approved
CilostazolResveratrol may increase the anticoagulant activities of Cilostazol.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cimicoxib.Investigational
CinoxacinResveratrol may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe metabolism of Resveratrol can be decreased when combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cisplatin.Approved
CitalopramThe metabolism of Resveratrol can be decreased when combined with Citalopram.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Resveratrol.Approved
ClopidogrelResveratrol may increase the anticoagulant activities of Clopidogrel.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Resveratrol.Vet Approved
CloranololResveratrol may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenResveratrol may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneResveratrol may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Resveratrol is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensResveratrol may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Resveratrol.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Resveratrol.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Resveratrol.Experimental
Cyproterone acetateThe serum concentration of Resveratrol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateResveratrol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinResveratrol may increase the thrombogenic activities of Daidzein.Experimental
DalteparinResveratrol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidResveratrol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Resveratrol.Investigational
DarexabanResveratrol may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Resveratrol.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.Approved, Investigational
DefibrotideResveratrol may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Delapril.Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dersalazine.Investigational
DesipramineResveratrol may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinResveratrol may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Resveratrol.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.Approved
DesmoteplaseResveratrol may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Resveratrol.Approved, Investigational
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Resveratrol.Approved, Investigational
DextranResveratrol may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinResveratrol may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dibotermin alfa.Approved, Investigational
DicoumarolResveratrol may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolResveratrol may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolResveratrol may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Resveratrol.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Resveratrol.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Resveratrol.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Resveratrol.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Resveratrol.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Resveratrol.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Resveratrol.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Resveratrol.Approved, Investigational
DihydrostreptomycinResveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Resveratrol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Resveratrol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Resveratrol.Approved
DiphenadioneResveratrol may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleResveratrol may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleResveratrol may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.Approved, Investigational
DosulepinThe metabolism of Resveratrol can be decreased when combined with Dosulepin.Approved
DrospirenoneResveratrol may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaResveratrol may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Resveratrol.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Resveratrol.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Resveratrol.Investigational
Edetic AcidResveratrol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanResveratrol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Resveratrol is combined with Enalaprilat.Approved
EnoxacinResveratrol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinResveratrol may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Resveratrol.Experimental
EpanololResveratrol may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolResveratrol may increase the thrombogenic activities of Epimestrol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Resveratrol.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Resveratrol.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Resveratrol.Experimental
EplerenoneResveratrol may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinResveratrol may increase the anticoagulant activities of Eplivanserin.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Resveratrol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.Approved
EptifibatideResveratrol may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin.Approved
EquolResveratrol may increase the thrombogenic activities of Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Resveratrol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Resveratrol.Approved
EsatenololResveratrol may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Resveratrol.Approved, Investigational
EsmololResveratrol may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateResveratrol may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateResveratrol may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateResveratrol may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolResveratrol may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedResveratrol may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Resveratrol.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Resveratrol.Experimental
Ethyl biscoumacetateResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Resveratrol.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Resveratrol.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Resveratrol.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Resveratrol.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Resveratrol.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Resveratrol.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Resveratrol.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Resveratrol.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Resveratrol.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Resveratrol.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Resveratrol.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Resveratrol.Experimental
FibrinolysinResveratrol may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Resveratrol.Approved, Investigational
FleroxacinResveratrol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Resveratrol.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone.Approved, Investigational
FluindioneResveratrol may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineResveratrol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Resveratrol.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Resveratrol.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Resveratrol.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Resveratrol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone furoate.Approved
FluvoxamineThe metabolism of Resveratrol can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol.Approved, Nutraceutical, Vet Approved
FondaparinuxResveratrol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinResveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
GabexateResveratrol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinResveratrol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinResveratrol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Resveratrol.Approved, Withdrawn
GemifloxacinResveratrol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinResveratrol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinResveratrol may increase the thrombogenic activities of Genistein.Investigational
GentamicinResveratrol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AResveratrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Resveratrol.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Resveratrol.Approved, Investigational
GrepafloxacinResveratrol may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Resveratrol.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Resveratrol is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Hemoglobin crosfumaril.Experimental
HeparinResveratrol may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolResveratrol may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Resveratrol.Investigational
HydralazineResveratrol may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.Approved, Investigational
HydroxytyrosolResveratrol may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BResveratrol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Resveratrol.Approved
IbudilastResveratrol may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Resveratrol.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Resveratrol.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Resveratrol is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylResveratrol may increase the antiplatelet activities of Icosapent ethyl.Approved, Investigational, Nutraceutical
IdraparinuxResveratrol may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilResveratrol may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanResveratrol may increase the antiplatelet activities of Ifetroban.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Resveratrol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Resveratrol.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Resveratrol.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.Approved
IndenololResveratrol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Resveratrol.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Resveratrol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.Approved, Investigational
IsepamicinResveratrol may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Resveratrol.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Resveratrol is combined with Istaroxime.Investigational
KanamycinResveratrol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Resveratrol.Experimental
KetanserinResveratrol may increase the antiplatelet activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.Approved, Vet Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Resveratrol.Experimental
LandiololResveratrol may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Resveratrol.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Resveratrol.Approved, Investigational
LepirudinResveratrol may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanResveratrol may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololResveratrol may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololResveratrol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinResveratrol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Resveratrol.Approved, Investigational
LidocaineThe metabolism of Resveratrol can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Resveratrol.Approved, Investigational
LinsidomineResveratrol may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Resveratrol.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Resveratrol.Approved, Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Resveratrol.Experimental
LobeglitazoneThe metabolism of Resveratrol can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinResveratrol may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Resveratrol.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Resveratrol.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Resveratrol.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Resveratrol.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Resveratrol.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Resveratrol.Vet Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Resveratrol.Illicit, Investigational, Withdrawn
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Resveratrol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.Approved
MelagatranResveratrol may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.Approved, Vet Approved
MepindololResveratrol may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Resveratrol.Approved
MestranolResveratrol may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Resveratrol.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Resveratrol.Experimental
MethallenestrilResveratrol may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Resveratrol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Methyl salicylate.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Resveratrol.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Resveratrol.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Resveratrol.Experimental
MetipranololResveratrol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Resveratrol.Experimental
MexiletineThe metabolism of Resveratrol can be decreased when combined with Mexiletine.Approved, Investigational
MicronomicinResveratrol may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Resveratrol can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Resveratrol.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Resveratrol.Approved, Investigational
MilrinoneMilrinone may increase the antiplatelet activities of Resveratrol.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Resveratrol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Resveratrol.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol.Approved
MoxestrolResveratrol may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Resveratrol.Approved
NadololResveratrol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinResveratrol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Resveratrol.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol.Approved
NaftopidilResveratrol may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidResveratrol may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 1022.Investigational
NeamineResveratrol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololResveratrol may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Resveratrol.Approved, Withdrawn
NemonoxacinResveratrol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Resveratrol.Approved, Investigational
NetilmicinResveratrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NevirapineThe metabolism of Resveratrol can be decreased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Resveratrol.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Resveratrol.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.Approved
NimesulideResveratrol may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Resveratrol.Investigational
NorfloxacinResveratrol may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.Approved, Investigational
OfloxacinResveratrol may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Resveratrol.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Resveratrol is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Resveratrol is combined with Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Resveratrol.Approved, Nutraceutical
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Resveratrol.Vet Approved
OsimertinibThe serum concentration of Resveratrol can be decreased when it is combined with Osimertinib.Approved
OtamixabanResveratrol may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Resveratrol.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.Approved
Oxolinic acidResveratrol may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololResveratrol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Resveratrol.Approved, Withdrawn
OzagrelResveratrol may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Resveratrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Parecoxib.Approved
ParnaparinResveratrol may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Resveratrol.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Resveratrol.Approved, Investigational
PazufloxacinResveratrol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinResveratrol may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololResveratrol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateResveratrol may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Resveratrol.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Resveratrol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Resveratrol.Experimental
PhenindioneResveratrol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Resveratrol can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonResveratrol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.Approved, Vet Approved
PicotamideResveratrol may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.Approved, Investigational
PindololResveratrol may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidResveratrol may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Resveratrol.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Resveratrol.Approved, Investigational
Piromidic acidResveratrol may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Resveratrol.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Resveratrol.Approved
PitolisantThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorResveratrol may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinResveratrol may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateResveratrol may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pomalidomide.Approved
Potassium CitrateResveratrol may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololResveratrol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Resveratrol.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Resveratrol.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone sulfate.Investigational
PrasugrelResveratrol may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Resveratrol.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Resveratrol can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Resveratrol.Experimental
PromestrieneResveratrol may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Resveratrol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Resveratrol.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Resveratrol.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Resveratrol.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Resveratrol.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Resveratrol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Resveratrol.Vet Approved
Protein CResveratrol may increase the anticoagulant activities of Protein C.Approved
Protein S humanResveratrol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeResveratrol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinResveratrol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Resveratrol.Investigational
PuromycinResveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Quinapril.Approved, Investigational
QuinestrolResveratrol may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.Approved
RamatrobanResveratrol may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ramipril.Approved
RelcovaptanResveratrol may increase the antiplatelet activities of Relcovaptan.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Rescinnamine.Approved
ReteplaseResveratrol may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinResveratrol may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinResveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Resveratrol.Approved
RifampicinThe metabolism of Resveratrol can be increased when combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Resveratrol.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.Approved, Investigational
RivaroxabanResveratrol may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Resveratrol.Approved, Investigational, Withdrawn
RopiniroleThe metabolism of Resveratrol can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinResveratrol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Resveratrol can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinResveratrol may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Resveratrol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Resveratrol.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Resveratrol.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Resveratrol.Approved, Investigational
SarpogrelateResveratrol may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseResveratrol may increase the anticoagulant activities of Saruplase.Experimental
SecoisolariciresinolResveratrol may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SelexipagResveratrol may increase the anticoagulant activities of Selexipag.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Resveratrol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Resveratrol.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Resveratrol.Investigational
SertralineSertraline may increase the antiplatelet activities of Resveratrol.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Resveratrol.Approved, Vet Approved
SimeprevirThe metabolism of Resveratrol can be decreased when combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Resveratrol.Approved
SisomicinResveratrol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinResveratrol may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding can be increased when Resveratrol is combined with Sodium Citrate.Approved, Investigational
SotalolResveratrol may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinResveratrol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Resveratrol.Investigational
StreptokinaseResveratrol may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinResveratrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Sulfasalazine.Approved
SulodexideResveratrol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Resveratrol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Resveratrol.Experimental
Synthetic Conjugated Estrogens, AResveratrol may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BResveratrol may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusResveratrol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Resveratrol.Approved
TalinololResveratrol may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Resveratrol.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Resveratrol.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.Approved, Investigational
TemafloxacinResveratrol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Temocapril.Experimental, Investigational
TenecteplaseResveratrol may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Resveratrol.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Resveratrol.Vet Approved
TerbutalineResveratrol may decrease the antihypertensive activities of Terbutaline.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Resveratrol.Experimental
TeriflunomideThe serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.Approved
TertatololResveratrol may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneResveratrol may increase the antiplatelet activities of Tesmilifene.Investigational
TheophyllineThe metabolism of Resveratrol can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.Approved
TiboloneResveratrol may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorResveratrol may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineThe metabolism of Resveratrol can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololResveratrol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Resveratrol.Investigational
TinzaparinResveratrol may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolResveratrol may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Resveratrol.Approved, Investigational
TirofibanResveratrol may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tixocortol.Approved, Withdrawn
TobramycinResveratrol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Resveratrol.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Resveratrol.Approved
TositumomabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Trandolapril.Approved
TranilastResveratrol may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrapidilResveratrol may increase the antiplatelet activities of Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone.Approved, Vet Approved
TriamtereneResveratrol may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Resveratrol.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
TriflusalResveratrol may increase the anticoagulant activities of Triflusal.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Resveratrol.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Trolamine salicylate.Approved
TrovafloxacinResveratrol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinResveratrol may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Resveratrol.Approved, Investigational
UrokinaseResveratrol may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Resveratrol.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.Approved, Investigational
VemurafenibThe serum concentration of Resveratrol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Resveratrol.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Resveratrol.Approved, Nutraceutical, Vet Approved
VorapaxarResveratrol may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinResveratrol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranResveratrol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Resveratrol.Approved, Investigational
ZeranolResveratrol may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Resveratrol.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Resveratrol.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Resveratrol.Withdrawn
ZucapsaicinThe metabolism of Resveratrol can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Philippe Jeandet, Roger Bessis, Marielle Adrian, Jean-Claude Yvin, Jean-Marie Joubert, "Use of aluminium chloride as a resveratrol synthesis elicitor." U.S. Patent US6080701, issued August, 1991.

US6080701
General References
  1. Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. [PubMed:16401555]
  2. Renaud S, Ruf JC: The French paradox: vegetables or wine. Circulation. 1994 Dec;90(6):3118-9. [PubMed:7994864]
  3. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002 Jan 30;50(3):431-5. [PubMed:11804508]
  4. Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003 Sep 24;51(20):5867-70. [PubMed:13129286]
  5. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27. [PubMed:15333514]
  6. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M: Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008 Feb 1;75(3):677-87. Epub 2007 Sep 18. [PubMed:17959154]
  7. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. [PubMed:10551373]
  8. N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Carpentier R, Hotchandani S, Tajmir-Riahi HA: Resveratrol binding to human serum albumin. J Biomol Struct Dyn. 2006 Dec;24(3):277-83. [PubMed:17054386]
External Links
Human Metabolome Database
HMDB0003747
KEGG Compound
C03582
PubChem Compound
445154
PubChem Substance
46504705
ChemSpider
392875
BindingDB
23926
ChEBI
45713
ChEMBL
CHEMBL165
Therapeutic Targets Database
DNC001205
PharmGKB
PA165291838
HET
STL
Wikipedia
Resveratrol
PDB Entries
1cgz / 1dvs / 1sg0 / 1u0w / 1z1f / 2jiz / 2l98 / 2ydx / 3ckl / 3fts
show 14 more
MSDS
Download (16.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDiabetic Nephropathies1
1Active Not RecruitingTreatmentDiastolic Heart Failure / Heart Failure With Preserved Ejection Fraction (HFpEF) / High Blood Pressure (Hypertension) / Hypertensive Heart Disease / Oxidative Stress1
1CompletedNot AvailableMemory1
1CompletedBasic ScienceHealthy, no Evidence of Disease1
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedPreventionHealthy, no Evidence of Disease1
1CompletedPreventionUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Stage I Colon Cancer / Stage I Rectal Cancer / Stage II Colon Cancer / Stage II Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer1
1CompletedTreatmentCancers / Malignant Neoplasm of Colon1
1CompletedTreatmentParkinson's Disease (PD)4
1, 2CompletedTreatmentFriedreich's Ataxia1
2Active Not RecruitingSupportive CareMitochondrial Function / Physical Function1
2Active Not RecruitingTreatmentAging1
2CompletedBasic ScienceDyslipidemias / Insulin Resistance1
2CompletedBasic ScienceSedentary Lifestyle1
2CompletedPreventionSchizophrenic Disorders1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentBMI >30 kg/m2 / Diabetes Mellitus (DM)1
2CompletedTreatmentInsulin Resistance / Type 2 Diabetes Mellitus1
2CompletedTreatmentMetabolic Syndromes1
2RecruitingDiagnosticCongestive Heart Failure Chronic1
2RecruitingTreatmentLymphangioleiomyomatosis1
2TerminatedTreatmentType 2 Diabetes Mellitus1
2Unknown StatusTreatmentFollicular Lymphoma (FL)1
2WithdrawnTreatmentInsulin Resistance1
3Enrolling by InvitationBasic ScienceMetabolic Syndromes1
3Not Yet RecruitingPreventionInfertilities1
3RecruitingSupportive CareKnee Osteoarthritis (Knee OA) / Primary Knee Osteoarthritis1
4CompletedTreatmentEndometriosis1
4Not Yet RecruitingTreatmentAcute Pancreatitis (AP) / Gastrointestinal Diseases1
Not AvailableCompletedPreventionEndothelial Disfunction / Lipid Metabolism Disorders / Vascular System Injuries1
Not AvailableCompletedTreatmentHepatitis1
Not AvailableCompletedTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableCompletedTreatmentViral Hepatitis B1
Not AvailableUnknown StatusNot AvailableEye Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)254 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0688 mg/mLALOGPS
logP2.57ALOGPS
logP3.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)-6.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.46 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.59
Caco-2 permeable+0.8915
P-glycoprotein substrateNon-substrate0.6501
P-glycoprotein inhibitor INon-inhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.9612
Renal organic cation transporterNon-inhibitor0.8634
CYP450 2C9 substrateNon-substrate0.7519
CYP450 2D6 substrateNon-substrate0.9288
CYP450 3A4 substrateNon-substrate0.7143
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.7068
CYP450 2D6 inhibitorNon-inhibitor0.9226
CYP450 2C19 inhibitorInhibitor0.8052
CYP450 3A4 inhibitorInhibitor0.7539
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8559
Ames testNon AMES toxic0.8407
CarcinogenicityNon-carcinogens0.7825
BiodegradationNot ready biodegradable0.8499
Rat acute toxicity1.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8933
hERG inhibition (predictor II)Non-inhibitor0.9462
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0006-1853900000-4919511a11ec24935434
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-0006-1853900000-4919511a11ec24935434
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 50V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 60V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 40V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 50V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 60V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 40V, NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0090000000-d9def7cee71fb7a40786
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004r-0970000000-f8c7ca07f27bfc1b8bda
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-0900000000-b1333b06db343c38f529
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014l-0900000000-c856c7fa9653868e5785
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004r-0950000000-8e44b9aa58ac75282058
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000f-0900000000-2b750fcfd933ce8809f2
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-014i-0900000000-79bf3bfcbb7bcdd0ffd2
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-014i-0900000000-9340e3fe04d435cf8475
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-004i-0590000000-4a9b53d6aad6ed8189d2
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-00kf-0900000000-b0f6bf3388d96335d77e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0390000000-f19a725fa516c1ccd06d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4r-1900000000-12ac653b70e86d051e9a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4l-3900000000-cddc9dc871ae0131587d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aov-4900000000-085c30542d4dbecc9a30
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0390000000-f8caace8d6c937282e65
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052r-1900000000-d06e6e1c144b2d48b364
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aou-3900000000-bb14be278509155e8ce6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-016r-8900000000-7a10869ce89fa2c7828f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0290000000-9742e3e8991c1c0c270d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002r-0940000000-07826509d63ca5c6ed72
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0910000000-2cac03dc9e9b045fdf23
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002r-0940000000-fb2be32a94602011c1b2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0920000000-4b294faea28304389dcf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0910000000-7cfbcea1e1b612e05a02
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0910000000-93888a6f43e37bc70298
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-1890000000-5a90c0c5508894cb16af
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2910000000-e0183692948660939c19
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ar9-0910000000-b498b69c984c5f85498e

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Styrenes / Resorcinols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Stilbene / Styrene / Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
resveratrol (CHEBI:45713) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes, Stilbenes (C03582) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes (LMPK13090005)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nadph dehydrogenase (quinone) activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
Gene Name
NQO2
Uniprot ID
P16083
Uniprot Name
Ribosyldihydronicotinamide dehydrogenase [quinone]
Molecular Weight
25918.4 Da
References
  1. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004 Sep 14;43(36):11417-26. [PubMed:15350128]
  2. Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun. 2004 Oct 22;323(3):743-9. [PubMed:15381063]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated ser...
Gene Name
CSNK2A1
Uniprot ID
P68400
Uniprot Name
Casein kinase II subunit alpha
Molecular Weight
45143.25 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function
Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. Converts ...
Gene Name
ALOX15
Uniprot ID
P16050
Uniprot Name
Arachidonate 15-lipoxygenase
Molecular Weight
74803.795 Da
References
  1. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34. [PubMed:10491155]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34. [PubMed:10491155]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription regulatory region dna binding
Specific Function
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
Gene Name
AHR
Uniprot ID
P35869
Uniprot Name
Aryl hydrocarbon receptor
Molecular Weight
96146.705 Da
References
  1. de Medina P, Casper R, Savouret JF, Poirot M: Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J Med Chem. 2005 Jan 13;48(1):287-91. [PubMed:15634023]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Together with PI4K2A and the type III PI4Ks (PIK4CA and PIK4CB) it contributes to the overall PI4-kinase activity of the cell. This contribution may be especially significant in plasma membrane, endosomal and Golgi compartments. The phosphorylation of phosphatidylinositol (PI) to PI4P is the first committed step in the generation of phosphatidylinositol 4,5-bisphosphate (PIP2), a precursor of the second messenger inositol 1,4,5-trisphosphate (InsP3). Contributes to the production of InsP3 in stimulated cells and is likely to be involved in the regulation of vesicular trafficking.
Specific Function
1-phosphatidylinositol 4-kinase activity
Gene Name
PI4K2B
Uniprot ID
Q8TCG2
Uniprot Name
Phosphatidylinositol 4-kinase type 2-beta
Molecular Weight
54743.71 Da
References
  1. Srivastava R, Ratheesh A, Gude RK, Rao KV, Panda D, Subrahmanyam G: Resveratrol inhibits type II phosphatidylinositol 4-kinase: a key component in pathways of phosphoinositide turn over. Biochem Pharmacol. 2005 Oct 1;70(7):1048-55. [PubMed:16102733]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881).
Specific Function
Epidermal growth factor receptor binding
Gene Name
ITGA5
Uniprot ID
P08648
Uniprot Name
Integrin alpha-5
Molecular Weight
114535.52 Da
References
  1. Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY: Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013 Dec;4(6):335-42. doi: 10.1007/s12672-013-0156-8. Epub 2013 Aug 14. [PubMed:23943159]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Wil...
Gene Name
ITGB3
Uniprot ID
P05106
Uniprot Name
Integrin beta-3
Molecular Weight
87056.975 Da
References
  1. Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY: Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013 Dec;4(6):335-42. doi: 10.1007/s12672-013-0156-8. Epub 2013 Aug 14. [PubMed:23943159]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transition metal ion binding
Specific Function
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
Gene Name
APP
Uniprot ID
P05067
Uniprot Name
Amyloid beta A4 protein
Molecular Weight
86942.715 Da
References
  1. Ahn JS, Lee JH, Kim JH, Paik SR: Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. Anal Biochem. 2007 Aug 15;367(2):259-65. Epub 2007 May 26. [PubMed:17597573]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
SNCA
Uniprot ID
P37840
Uniprot Name
Alpha-synuclein
Molecular Weight
14460.155 Da
References
  1. Ahn JS, Lee JH, Kim JH, Paik SR: Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. Anal Biochem. 2007 Aug 15;367(2):259-65. Epub 2007 May 26. [PubMed:17597573]
Details
13. Estrogen receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, Forti L, Stivala LA, Iacopetta D, Dolce V, Ando S, Pezzi V, Maggiolini M: Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res. 2009 Jul;53(7):845-58. doi: 10.1002/mnfr.200800331. [PubMed:19496085]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Organic cyclic compound binding
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1A
Uniprot ID
P48039
Uniprot Name
Melatonin receptor type 1A
Molecular Weight
39374.315 Da
References
  1. Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, Leclerc V, Yous S, Delagrange P, Boutin JA: Old and new inhibitors of quinone reductase 2. Chem Biol Interact. 2010 Jul 30;186(2):103-9. doi: 10.1016/j.cbi.2010.04.006. Epub 2010 May 4. [PubMed:20399199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Melatonin receptor activity
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1B
Uniprot ID
P49286
Uniprot Name
Melatonin receptor type 1B
Molecular Weight
40187.895 Da
References
  1. Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, Leclerc V, Yous S, Delagrange P, Boutin JA: Old and new inhibitors of quinone reductase 2. Chem Biol Interact. 2010 Jul 30;186(2):103-9. doi: 10.1016/j.cbi.2010.04.006. Epub 2010 May 4. [PubMed:20399199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Carbohydrate binding
Specific Function
Not Available
Gene Name
CLEC14A
Uniprot ID
Q86T13
Uniprot Name
C-type lectin domain family 14 member A
Molecular Weight
51635.005 Da
References
  1. Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C: Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010 Nov 15;19(22):4319-29. doi: 10.1093/hmg/ddq354. Epub 2010 Aug 20. [PubMed:20729295]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Curator comments
Antagonist at the canonical form of the receptor. Agonist at isoform 3 of the receptor.
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
References
  1. Salas M, Obando P, Ojeda L, Ojeda P, Perez A, Vargas-Uribe M, Rivas CI, Vera JC, Reyes AM: Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. Am J Physiol Cell Physiol. 2013 Jul 1;305(1):C90-9. doi: 10.1152/ajpcell.00387.2012. Epub 2013 Apr 24. [PubMed:23615963]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
Resveratrol inhibits CBR1 with a mix of competitive and non-competitive kinetics.
General Function
Prostaglandin-e2 9-reductase activity
Specific Function
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. ...
Gene Name
CBR1
Uniprot ID
P16152
Uniprot Name
Carbonyl reductase [NADPH] 1
Molecular Weight
30374.73 Da
References
  1. Ito Y, Mitani T, Harada N, Isayama A, Tanimori S, Takenaka S, Nakano Y, Inui H, Yamaji R: Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol (Tokyo). 2013;59(4):358-64. [PubMed:24064738]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17. [PubMed:24454499]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17. [PubMed:24454499]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine/tyrosine kinase activity
Specific Function
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, ...
Gene Name
AKT1
Uniprot ID
P31749
Uniprot Name
RAC-alpha serine/threonine-protein kinase
Molecular Weight
55686.035 Da
References
  1. Hsieh TC, Lin CY, Bennett DJ, Wu E, Wu JM: Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One. 2014 Jun 26;9(6):e101070. doi: 10.1371/journal.pone.0101070. eCollection 2014. [PubMed:24968355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Binds to the dendritic targeting element and may play a role in mRNA trafficking (By similarity). Part of a ternary complex that binds to the downstream control sequence (DCS) of the pre-mRNA. Mediates exon inclusion in transcripts that are subject to tissue-specific alternative splicing. May interact with single-stranded DNA from the far-upstream element (FUSE). May activate gene expression. Also involved in degradation of inherently unstable mRNAs that contain AU-rich elements (AREs) in their 3'-UTR, possibly by recruiting degradation machinery to ARE-containing mRNAs.
Specific Function
Dna binding
Gene Name
KHSRP
Uniprot ID
Q92945
Uniprot Name
Far upstream element-binding protein 2
Molecular Weight
73115.16 Da
References
  1. Bollmann F, Art J, Henke J, Schrick K, Besche V, Bros M, Li H, Siuda D, Handler N, Bauer F, Erker T, Behnke F, Monch B, Hardle L, Hoffmann M, Chen CY, Forstermann U, Dirsch VM, Werz O, Kleinert H, Pautz A: Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity. Nucleic Acids Res. 2014 Nov 10;42(20):12555-69. doi: 10.1093/nar/gku1033. Epub 2014 Oct 28. [PubMed:25352548]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tyrosine-trna ligase activity
Specific Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
Gene Name
YARS
Uniprot ID
P54577
Uniprot Name
Tyrosine--tRNA ligase, cytoplasmic
Molecular Weight
59143.025 Da
References
  1. Sajish M, Schimmel P: A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 2015 Mar 19;519(7543):370-3. doi: 10.1038/nature14028. Epub 2014 Dec 22. [PubMed:25533949]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085]
  2. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
  2. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085]
Details
3. Cytochrome P450 1B1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
Details
4. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155. Epub 2010 Aug 17. [PubMed:20716633]
  2. Piver B, Berthou F, Dreano Y, Lucas D: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 2001 Dec 15;125(1-3):83-91. [PubMed:11701226]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name
TTR
Uniprot ID
P02766
Uniprot Name
Transthyretin
Molecular Weight
15886.88 Da
References
  1. Commodari F, Khiat A, Ibrahimi S, Brizius AR, Kalkstein N: Comparison of the phytoestrogen trans-resveratrol (3,4',5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn Reson Chem. 2005 Jul;43(7):567-72. [PubMed:15809979]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lu Z, Zhang Y, Liu H, Yuan J, Zheng Z, Zou G: Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J Fluoresc. 2007 Sep;17(5):580-7. Epub 2007 Jun 28. [PubMed:17597382]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:55